Jacobio Pharmaceuticals Co. Ltd.
http://en.jacobiopharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Jacobio Pharmaceuticals Co. Ltd.
Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive
The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.
China’s KRAS Race: Homegrown Contenders Play Catch-Up
The sizzling race for China’s first approved KRAS inhibitor has seen Amgen/BeiGene’s Lumakras drop out and Mirati/Zai Lab’s Krazati lag in a confirmatory Phase III trial, while domestic fast-followers are in the meantime eyeing their first approval filings by the end of this year.
Merck KGaA’s Oncology Sales And Pipeline Updates Dominate Q3 Earnings
The German firm’s oncology franchise grew to more than €400m in the third quarter as sales of Bavencio doubled, while anticancer partnerships and pipeline updates drew interest.
Roche Goes Big On KRAS-Mutated Cancers In Hookipa Pact
Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice